Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 11, 2024
Grant Date -
Aug 27, 2020
app pub date -
May 22, 2018
filing date -
May 24, 2017
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully